BHB-1893
Hypertrophic Cardiomyopathy (Obstructive and Non-obstructive)
Phase 3Active
Key Facts
Indication
Hypertrophic Cardiomyopathy (Obstructive and Non-obstructive)
Phase
Phase 3
Status
Active
Company
About Braveheart Bio
Braveheart Bio is a private, pre-revenue biotech company advancing BHB-1893, a selective cardiac myosin inhibitor for hypertrophic cardiomyopathy (HCM). The company is positioned in a competitive but high-need cardiovascular space, with its candidate designed for greater convenience and accessibility compared to existing therapies. Recent positive Phase 2 results from a partnership with Hengrui Pharma in China and a seasoned leadership team provide momentum as the program advances into late-stage trials. The company aims to address significant unmet needs in both obstructive and non-obstructive HCM.
View full company profile